• News
  • SAN DIEGO
  • BioTech

Santarus launches colitis drug

Santarus Inc., a specialty biotech company in Carmel Valley, has begun the U.S. launch of Uceris, a treatment for patients with mild or moderate ulcerative colitis.

The move comes one month after the U.S. Food and Drug Administration granted approval for Uceris, which was jointly developed by Santarus and Italy’s Cosmo Technologies.

To promote the drug, Santarus (Nasdaq: SNTS) has hired 85 new sales representatives, bringing its total number of sales reps to 235. The company plans to use its entire sales organization to promote Uceris and another drug, Zegerid, to gastroenterologists, while also continuing to promote its three diabetes/metabolic products to endocrinologists and other physicians, said William C. Denby, senior vice president of commercial operations.

Zegerid is a treatment for heartburn and other symptoms of gastroesophageal reflux disease.

“In addition to our physician outreach, we are implementing patient education programs through social media and medical information websites to provide patients with helpful information about treatment options,” Denby said.

Upon the first commercial sale of Uceris, $7 million is payable to Cosmo in cash or Santarus common stock, at Cosmo’s option.

Because the move has been expected, Santarus’ stock price was flat during morning trading on Wall Street. Its stock price was hovering around $13.40, roughly 20 cents below its 52-week high and $1.30 below the all-time high that it hit in June 2004, three months after it entered the stock market.

RELATED ARTICLES:

Appeals court finds some Santarus patents valid

Freedom Meditech receives 510(k) clearance for ophthalmic device

CareFusion unveils take-apart laparoscopic scissors

FDA clears two Life Technologies products

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Santarus Inc.

Company Website

10590 W. Ocean Air Drive., Suite 200
San Diego, CA 92130

Santarus Inc. Executive(s):

Gerald Proehl

  • Chief Executive Officer, President

Related Videos

Entrepreneur Of The Year 2013 semifinalist: Gerald Proehl

May 7, 2013 -- George Chamberlin speaks with Gerald Proehl, director/president/CEO of Santarus Inc., about the highs and lows of operating a biotech company. Proehl is a semifinalist in the Ernst & Young Entrepreneur Of The Year 2013 San Diego awards.

View all the videos in this series.

Similar Companies

NAICS - 424210 - Drugs and Druggists' Sundries Merchant Wholesalers
Subscribe Today!